Monoclonal Antibody LpMab-9 Recognizes O-glycosylated N-Terminus of Human Podoplanin

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy

Volumn 34, Issue 5, 2015, Pages 310-317

  Kaneko, Mika K ^a   Oki, Hiroharu ^a,b   Hozumi, Yasukazu ^b   Liu, Xing ^a,b   Ogasawara, Satoshi ^a   Takagi, Michiaki ^b   Goto, Kaoru ^b   Kato, Yukinari ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b YAMAGATA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCAN; LECTIN; LPMAB 9; MONOCLONAL ANTIBODY; MUCIN; PODOPLANIN; SIALIC ACID; UNCLASSIFIED DRUG; MEMBRANE PROTEIN; PDPN PROTEIN, HUMAN;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; EPITOPE MAPPING; FEMALE; FLOW CYTOMETRY; GLIOBLASTOMA; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; PROTEIN MICROARRAY; SIALYLATION; SURFACE PLASMON RESONANCE; WESTERN BLOTTING; ANIMAL; CELL LINE; CHO CELL LINE; CRICETULUS; ENDOTHELIUM CELL; FIBROBLAST; GLYCOSYLATION; HEK293 CELL LINE; IMMUNOLOGY; LUNG TUMOR; THROMBOCYTE AGGREGATION; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE; CELL LINE, TUMOR; CHO CELLS; CRICETULUS; ENDOTHELIAL CELLS; FIBROBLASTS; GLYCOSYLATION; HEK293 CELLS; HUMANS; LUNG NEOPLASMS; MEMBRANE GLYCOPROTEINS; PLATELET AGGREGATION;

EID: 84945564601     PISSN: None     EISSN: 21679436     Source Type: Journal    
DOI: 10.1089/mab.2015.0022     Document Type: Article

References (41)

1. Kato Y, Fujita N, Kunita A, Sato S, Kaneko M, Osawa M, Tsuruo T: Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors. J Biol Chem 2003;278:51599-51605.
2. Kaneko MK, Kato Y, Kitano T, Osawa M: Conservation of a platelet activating domain of Aggrus/podoplanin as a platelet aggregation-inducing factor. Gene 2006;378: 52-57.
3. Kato Y, Sasagawa I, Kaneko M, Osawa M, Fujita N, Tsuruo T: Aggrus: a diagnostic marker that distinguishes seminoma from embryonal carcinoma in testicular germ cell tumors. Oncogene 2004;23:8552-8556.
4. Martin-Villar E, Scholl FG, Gamallo C, Yurrita MM, Munoz-Guerra M, Cruces J, Quintanilla M: Characterization of human PA2.26 antigen (T1alpha-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas. Int J Cancer 2005;113:899-910.
5. Kato Y, Kaneko M, Sata M, Fujita N, Tsuruo T, Osawa M: Enhanced expression of Aggrus (T1alpha/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma. Tumor Biol 2005;26:195-200.
6. Yuan P, Temam S, El-Naggar A, Zhou X, Liu D, Lee J, Mao L: Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer 2006;107: 563-569.
7. Kato Y, Kaneko MK, Kuno A, Uchiyama N, Amano K, Chiba Y, Hasegawa Y, Hirabayashi J, Narimatsu H, Mishima K, Osawa M: Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain. Biochem Biophys Res Commun 2006;349:1301-1307.
8. Mishima K, Kato Y, Kaneko MK, Nakazawa Y, Kunita A, Fujita N, Tsuruo T, Nishikawa R, Hirose T, Matsutani M: Podoplanin expression in primary central nervous system germ cell tumors: a useful histological marker for the diagnosis of germinoma. Acta Neuropathol (Berl) 2006; 111:563-568.
9. Mishima K, Kato Y, Kaneko MK, Nishikawa R, Hirose T, Matsutani M: Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol (Berl) 2006;111: 483-488.
10. Abe S, Morita Y, Kaneko MK, Hanibuchi M, Tsujimoto Y, Goto H, Kakiuchi S, Aono Y, Huang J, Sato S, Kishuku M, Taniguchi Y, Azuma M, Kawazoe K, Sekido Y, Yano S, Akiyama S, Sone S, Minakuchi K, Kato Y, Nishioka Y: A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody. J Immunol 2013;190:6239-6249.
11. Takagi S, Oh-hara T, Sato S, Gong B, Takami M, Fujita N: Expression of Aggrus/podoplanin in bladder cancer and its role in pulmonary metastasis. Int J Cancer 2014;134:2605-2614.
12. Kunita A, Kashima TG, Ohazama A, Grigoriadis AE, Fukayama M: Podoplanin is regulated by AP-1 and promotes platelet aggregation and cell migration in osteosarcoma. Am J Pathol 2011;179:1041-1049.
13. Chandramohan V, Bao X, Kato Kaneko M, Kato Y, Keir ST, Szafranski SE, Kuan CT, Pastan IH, Bigner DD: Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors. Int J Cancer 2013; 132:2339-2348.
14. Kato Y, Vaidyanathan G, Kaneko MK, Mishima K, Srivastava N, Chandramohan V, Pegram C, Keir ST, Kuan CT, Bigner DD, Zalutsky MR: Evaluation of antipodoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas. Nucl Med Biol 2010;37:785-794.
15. Kawase A, Ishii G, Nagai K, Ito T, Nagano T, Murata Y, Hishida T, Nishimura M, Yoshida J, Suzuki K, Ochiai A: Podoplanin expression by cancer associated fibroblasts predicts poor prognosis of lung adenocarcinoma. Int J Cancer 2008;123:1053-1059.
16. Hoshino A, Ishii G, Ito T, Aoyagi K, Ohtaki Y, Nagai K, Sasaki H, Ochiai A: Podoplanin-positive fibroblasts enhance lung adenocarcinoma tumor formation: podoplanin in fibroblast functions for tumor progression. Cancer Res 2011;71:4769-4779.
17. Schoppmann SF, Jesch B, Riegler MF, Maroske F, Schwameis K, Jomrich G, Birner P: Podoplanin expressing cancer associated fibroblasts are associated with unfavourable prognosis in adenocarcinoma of the esophagus. Clin Exp Metastasis 2013;30:441-446.
18. Shindo K, Aishima S, Ohuchida K, Fujiwara K, Fujino M, Mizuuchi Y, Hattori M, Mizumoto K, Tanaka M, Oda Y: Podoplanin expression in cancer-associated fibroblasts enhances tumor progression of invasive ductal carcinoma of the pancreas. Mol Cancer 2013;12:168.
19. Inoue H, Tsuchiya H, Miyazaki Y, Kikuchi K, Ide F, Sakashita H, Kusama K: Podoplanin expressing cancerassociated fibroblasts in oral cancer. Tumour Biol 2014;35: 11345-11352.
20. Nagae M, Morita-Matsumoto K, Kato M, Kaneko MK, Kato Y, Yamaguchi Y: A platform of C-type lectin-like receptor CLEC-2 for binding O-glycosylated podoplanin and nonglycosylated rhodocytin. Structure 2014;22:1711-1721.
21. Ogasawara S, Kaneko MK, Price JE, Kato Y: Characterization of anti-podoplanin monoclonal antibodies: critical epitopes for neutralizing the interaction between podoplanin and CLEC-2. Hybridoma 2008;27:259-267.
22. Takagi S, Sato S, Oh-hara T, Takami M, Koike S, Mishima Y, Hatake K, Fujita N: Platelets promote tumor growth and metastasis via direct interaction between Aggrus/podoplanin and CLEC-2. PLoS One 2013;8:e73609.
23. Marks A, Sutherland DR, Bailey D, Iglesias J, Law J, Lei M, Yeger H, Banerjee D, Baumal R: Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumours. Br J Cancer 1999;80:569-578.
24. Kato Y, Kaneko MK: A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin. Sci Rep 2014;4:5924.
25. Oki H, Kaneko MK, Ogasawara S, Tsujimoto Y, Liu X, Sugawara M, Takakubo Y, Takagi M, Kato Y: Characterization of a monoclonal antibody LpMab-7 recognizing non-PLAG domain of podoplanin. Monoclon Antib Immunodiagn Immunother 2015;34:174-180.
26. Kaneko MK, Oki H, Ogasawara S, Takagi M, Kato Y: An anti-podoplanin monoclonal antibody LpMab-7 detects metastatic legions of osteosarcoma Monoclon Antib Immunodiagn Immunother 2015;34:154-161.
27. Oki H, Ogasawara S, Kaneko MK, Takagi M, Yamauchi M, Kato Y: Characterization of monoclonal antibody LpMab-3 recognizing sialylated glycopeptide of podoplanin. Monoclon Antib Immunodiagn Immunother 2015;34: 44-50.
28. Kato Y: Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas. Brain Tumor Pathol 2014;32:3-11.
29. Kaneko MK, Tian W, Takano S, Suzuki H, Sawa Y, Hozumi Y, Goto K, Yamazaki K, Kitanaka C, Kato Y: Establishment of a novel monoclonal antibody SMab-1 specific for IDH1-R132S mutation. Biochem Biophys Res Commun 2011;406:608-613.
30. Kaneko MK, Kunita A, Abe S, Tsujimoto Y, Fukayama M, Goto K, Sawa Y, Nishioka Y, Kato Y: Chimeric antipodoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity. Cancer Sci 2012;103:1913-1919.
31. Kato Y, Kaneko MK, Kunita A, Ito H, Kameyama A, Ogasawara S, Matsuura N, Hasegawa Y, Suzuki-Inoue K, Inoue O, Ozaki Y, Narimatsu H: Molecular analysis of the pathophysiological binding of the platelet aggregationinducing factor podoplanin to the C-type lectin-like receptor CLEC-2. Cancer Sci 2008;99:54-61.
32. Kuno A, Kato Y, Matsuda A, Kaneko MK, Ito H, Amano K, Chiba Y, Narimatsu H, Hirabayashi J: Focused differential glycan analysis with the platform antibodyassisted lectin profiling for glycan-related biomarker verification. Mol Cell Proteomics 2009;8:99-108.
33. Kaneko MK, Kato Y, Kameyama A, Ito H, Kuno A, Hirabayashi J, Kubota T, Amano K, Chiba Y, Hasegawa Y, Sasagawa I, Mishima K, Narimatsu H: Functional glycosylation of human podoplanin: glycan structure of platelet aggregation-inducing factor. FEBS Lett 2007;581: 331-336.
34. Breiteneder-Geleff S, Matsui K, Soleiman A, Meraner P, Poczewski H, Kalt R, Schaffner G, Kerjaschki D: Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. Am J Pathol 1997;151:1141-1152.
35. Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong YK, Detmar M: Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol 2005;166:913-921.
36. Acton SE, Astarita JL, Malhotra D, Lukacs-Kornek V, Franz B, Hess PR, Jakus Z, Kuligowski M, Fletcher AL, Elpek KG, Bellemare-Pelletier A, Sceats L, Reynoso ED, Gonzalez SF, Graham DB, Chang J, Peters A, Woodruff M, Kim YA, Swat W, Morita T, Kuchroo V, Carroll MC, Kahn ML, Wucherpfennig KW, Turley SJ: Podoplanin-rich stromal networks induce dendritic cell motility via activation of the C-type lectin receptor CLEC-2. Immunity 2012; 37:276-289.
37. Astarita JL, Cremasco V, Fu J, Darnell MC, Peck JR, Nieves-Bonilla JM, Song K, Kondo Y, Woodruff MC, Gogineni A, Onder L, Ludewig B, Weimer RM, Carroll MC, Mooney DJ, Xia L, Turley SJ: The CLEC-2-podoplanin axis controls the contractility of fibroblastic reticular cells and lymph node microarchitecture. Nat Immunol 2015;16:75-84.
38. Acton SE, Farrugia AJ, Astarita JL, Mourao-Sa D, Jenkins RP, Nye E, Hooper S, van Blijswijk J, Rogers NC, Snelgrove KJ, Rosewell I, Moita LF, Stamp G, Turley SJ, Sahai E, Reis e Sousa C: Dendritic cells control fibroblastic reticular network tension and lymph node expansion. Nature 2014;514:498-502.
39. Bertozzi CC, Schmaier AA, Mericko P, Hess PR, Zou Z, Chen M, Chen CY, Xu B, Lu MM, Zhou D, Sebzda E, Santore MT, Merianos DJ, Stadtfeld M, Flake AW, Graf T, Skoda R, Maltzman JS, Koretzky GA, Kahn ML: Platelets regulate lymphatic vascular development through CLEC-2-SLP-76 signaling. Blood 2010;116:661-670.
40. Ogasawara S, Oki H, Kaneko MK, Hozumi Y, Liu X, Honma R, Fujii Y, Nakamura T, Goto K, Takagi M, Kato Y: Development of monoclonal antibody LpMab-10 recognizing non-PLAG1/2 domain including Thr34 of human podoplanin. Monoclon Antib Immunodiagn Immunother 2015;34:318-326.
41. Kato Y, Kunita A, Abe S, Ogasawara S, Fujii Y, Oki H, Fukayama M, Nishioka Y, Kaneko MK: The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastatis via ADCC and CDC rather than via its neutralizing activity. Oncotarget 2015; DOI: 10.18632/oncotarget.5339